Pharmaceuticals News

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial Proven record in advancing breakthrough autoimmune therapies and...

Late-breaking oral presentation at Retina Subspecialty Day outlines data from Beacon’s pivotal VISTA trial, which met its FDA-endorsed primary endpoint with statistical significance31.0% of...

The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective...

– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients...

ALAMEDA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting...

ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptomsLS mean change from baseline in Vh:Cd ratio of -0.17 on...

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance1 at 6 months, and these changes were maintained...

Bagsværd, Denmark, 12 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of...

Stillbirth affects families everywhere, but the burden is not shared equally: Of the nearly 2 million babies stillborn each year, almost half occur in sub-Saharan AfricaNew investment will focus on...

LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...